Onconetix, Inc. (ONCO) intrinsic value & 10-year financials
Onconetix, Inc. (ONCO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 273.4% a year to $815.4K, with an average return on invested capital of 125.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.48
- Market cap
- $449.0K
- Revenue (FY2025)
- $815.4K
- Revenue growth (6-yr CAGR)
- 273.4%
- ROIC (10-yr avg)
- 125.4%
- Free cash flow (FY2025)
- —
ONCO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $815.4K | -$14.0M | -$16.56 | — | -2190.0% | -169.0% |
| FY2024 | $2.5M | -$58.7M | -$21.45 | -$10.5M | -2238.0% | 550.5% |
| FY2023 | $58.5K | -$37.4M | -$2.19 | -$13.6M | -61634.5% | 357.3% |
| FY2022 | — | -$13.4M | -$1.10 | -$8.7M | — | -56.6% |
| FY2021 | — | -$3.4M | -$0.32 | -$2.0M | — | -55.3% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Onconetix, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Onconetix, Inc. has historically struggled to out-earn its cost of capital, averaging just -20.9% ROIC.
Onconetix, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Onconetix, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-550.05 per share.